JP4824890B2 - 免疫抑制剤として使用するためのデプシペプチドおよびその同族体 - Google Patents

免疫抑制剤として使用するためのデプシペプチドおよびその同族体 Download PDF

Info

Publication number
JP4824890B2
JP4824890B2 JP2001543579A JP2001543579A JP4824890B2 JP 4824890 B2 JP4824890 B2 JP 4824890B2 JP 2001543579 A JP2001543579 A JP 2001543579A JP 2001543579 A JP2001543579 A JP 2001543579A JP 4824890 B2 JP4824890 B2 JP 4824890B2
Authority
JP
Japan
Prior art keywords
cells
cell
lymphocytes
stimulation
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001543579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516418A5 (enExample
JP2003516418A (ja
Inventor
ソーレン スコフ，
Original Assignee
エクサイト セラピーズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4824890(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エクサイト セラピーズ インコーポレーティッド filed Critical エクサイト セラピーズ インコーポレーティッド
Publication of JP2003516418A publication Critical patent/JP2003516418A/ja
Publication of JP2003516418A5 publication Critical patent/JP2003516418A5/ja
Application granted granted Critical
Publication of JP4824890B2 publication Critical patent/JP4824890B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001543579A 1999-12-08 2000-12-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体 Expired - Fee Related JP4824890B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US60/169,731 1999-12-08
US19358200P 2000-03-30 2000-03-30
US60/193,582 2000-03-30
PCT/US2000/033169 WO2001042282A1 (en) 1999-12-08 2000-12-06 Depsipeptide and congeners thereof for use as immunosuppressants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011017260A Division JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Publications (3)

Publication Number Publication Date
JP2003516418A JP2003516418A (ja) 2003-05-13
JP2003516418A5 JP2003516418A5 (enExample) 2008-01-31
JP4824890B2 true JP4824890B2 (ja) 2011-11-30

Family

ID=26865325

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001543579A Expired - Fee Related JP4824890B2 (ja) 1999-12-08 2000-12-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2011017260A Withdrawn JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2013043969A Withdrawn JP2013107902A (ja) 1999-12-08 2013-03-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2014155914A Withdrawn JP2014205714A (ja) 1999-12-08 2014-07-31 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011017260A Withdrawn JP2011084585A (ja) 1999-12-08 2011-01-28 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2013043969A Withdrawn JP2013107902A (ja) 1999-12-08 2013-03-06 免疫抑制剤として使用するためのデプシペプチドおよびその同族体
JP2014155914A Withdrawn JP2014205714A (ja) 1999-12-08 2014-07-31 免疫抑制剤として使用するためのデプシペプチドおよびその同族体

Country Status (16)

Country Link
US (2) US6403555B1 (enExample)
EP (3) EP1246839B1 (enExample)
JP (4) JP4824890B2 (enExample)
KR (1) KR20020062956A (enExample)
CN (1) CN1414971A (enExample)
AT (3) ATE269354T1 (enExample)
AU (1) AU762525B2 (enExample)
BR (1) BR0016154A (enExample)
CA (1) CA2393682C (enExample)
DE (3) DE60011678T2 (enExample)
DK (1) DK1438966T3 (enExample)
ES (3) ES2282751T3 (enExample)
HK (1) HK1049849B (enExample)
IL (2) IL149995A0 (enExample)
PT (1) PT1438966E (enExample)
WO (1) WO2001042282A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
CN1871034B (zh) * 2003-07-09 2011-07-06 亨利福特保健系统公司 用新型腺病毒治疗癌症的方法和组合物
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006055621A2 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2621560A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
CN103497238A (zh) 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
WO2009078875A1 (en) * 2007-12-19 2009-06-25 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US20090280169A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2009141658A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
WO2009141657A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
ES2621849T3 (es) * 2009-06-26 2017-07-05 Sunny Pharmtech Inc. Método de tratamiento o mejora de toxicidades mucocutáneas u oculares.
TWI412359B (zh) * 2009-07-07 2013-10-21 Asan Lab Co Ltd 組織蛋白去乙醯酵素抑制劑在製備治療或減緩黏膜／皮膚或眼睛毒性或副作用之藥物的用途
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
WO2013047509A1 (ja) * 2011-09-30 2013-04-04 国立大学法人東北大学 新規ホスファチジルイノシトール３キナーゼ阻害剤及び医薬組成物
CA2866392C (en) 2012-03-30 2023-10-24 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TWI702046B (zh) * 2013-07-19 2020-08-21 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
CN110760564A (zh) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 细胞周期检测方法及其所用试剂与试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0285296A (ja) * 1988-07-26 1990-03-26 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１２２８物質およびその製造法
WO1997035990A2 (en) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
WO1999014241A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
CA2283161A1 (en) 1997-03-03 1998-09-11 Duke University Immunosuppression
DE19713626A1 (de) * 1997-04-02 1998-10-08 Bayer Ag Neue Thiodepsipeptide zur Bekämpfung von Endoparasiten und ein einfaches Verfahren zu ihrer Herstellung
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
NZ503061A (en) 1997-09-02 2001-08-31 Japan Energy Corp Cyclic tetrapeptide derivatives and use as anti-cancer agents
WO1999015174A1 (en) 1997-09-22 1999-04-01 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
WO1999025703A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
WO1999030730A1 (en) 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
EP0931792B1 (en) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides containing non-natural amino acids
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
DK1142905T3 (da) * 1999-01-13 2006-09-18 Astellas Pharma Inc Hidtil ukendt depsipeptidforbindelse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0285296A (ja) * 1988-07-26 1990-03-26 Fujisawa Pharmaceut Co Ltd Ｆｒ９０１２２８物質およびその製造法
US4977138A (en) * 1988-07-26 1990-12-11 Fujisawa Pharmaceutical Co., Ltd. FR901228 substance and preparation thereof
WO1997035990A2 (en) * 1996-03-26 1997-10-02 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
WO2001042282A1 (en) 2001-06-14
DE60011678D1 (de) 2004-07-22
DE60033453D1 (de) 2007-03-29
US20020045575A1 (en) 2002-04-18
DK1438966T3 (da) 2007-06-11
ATE269354T1 (de) 2004-07-15
ES2282751T3 (es) 2007-10-16
US6403555B1 (en) 2002-06-11
JP2014205714A (ja) 2014-10-30
EP1779859A2 (en) 2007-05-02
US6548479B1 (en) 2003-04-15
AU762525B2 (en) 2003-06-26
EP1246839B1 (en) 2004-06-16
CN1414971A (zh) 2003-04-30
EP1438966B1 (en) 2007-02-14
AU2068001A (en) 2001-06-18
JP2003516418A (ja) 2003-05-13
ES2347284T3 (es) 2010-10-27
CA2393682A1 (en) 2001-06-14
KR20020062956A (ko) 2002-07-31
PT1438966E (pt) 2007-05-31
CA2393682C (en) 2012-01-31
WO2001042282A9 (en) 2002-05-30
HK1049849A1 (en) 2003-05-30
EP1438966A2 (en) 2004-07-21
ES2225282T3 (es) 2005-03-16
IL149995A (en) 2009-09-01
EP1779859A3 (en) 2007-05-16
HK1070268A1 (en) 2005-06-17
DE60044542D1 (de) 2010-07-22
JP2011084585A (ja) 2011-04-28
JP2013107902A (ja) 2013-06-06
HK1049849B (en) 2004-12-03
EP1779859B1 (en) 2010-06-09
EP1438966A3 (en) 2004-08-04
DE60011678T2 (de) 2005-07-14
EP1246839A1 (en) 2002-10-09
BR0016154A (pt) 2003-02-25
ATE470447T1 (de) 2010-06-15
DE60033453T2 (de) 2007-11-29
ATE353663T1 (de) 2007-03-15
IL149995A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
EP1246839B1 (en) Depsipeptide and congeners thereof for use as immunosuppressants
US6828302B1 (en) Therapeutic uses of depsipeptides and congeners thereof
JP6102822B2 (ja) Ｔ細胞媒介性疾患の処置
JP2772372B2 (ja) シクロスポリン類およびそれらの医薬用途
US20090048297A1 (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CA2140931A1 (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune disease and tumour progression
CA1315478C (en) Tripeptide with immunostimulating activity
HK1070268B (en) Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101018

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110909

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140916

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees